title: Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
abstract: Vaccines against parainfluenza (PIV) and respiratory syncytial viruses (RSV) that are currently being developed include both live and subunit vaccines. Candidate live PIV vaccines that have been found to be attenuated and efficacious in rodents or primate models are (1) cold-adapted, temperature-sensitive mutants of PIV-type 3 that have been serially passaged at low temperature (20 degrees C) in simian kidney tissue culture; (2) protease-activation mutants (PIV-1-Sendai), which have mutations that decrease the cleavability of their F glycoprotein by host cell protease; (3) an animal virus, bovine PIV-3 virus, which is antigenically related to the human PIV-3 virus, and (4) vaccinia recombinant viruses bearing RSV or PIV-3 glycoproteins. Subunit RSV and PIV-3 viruses are being produced and evaluated as immunogens. A major concern with these vaccines is the possibility of disease potentiation following virus infection as occurred previously with formalin-inactivated measles and RSV vaccines. Studies indicate that PIV-3 and RSV glycoprotein vaccines are immunogenic and efficacious in animals but insufficient data exist to estimate their capacity to potentiate disease. However, since a cotton rat model is available to detect potentiated disease resulting from infection of cotton rats previously immunized with formalin-inactivated RSV vaccine, it is now possible to systematically evaluate new vaccines in experimental animals for disease potentiation before studies are initiated in humans. It is likely within the next several years that one or more of these PIV or RSV vaccines will be tested in humans for safety and immunogenicity.
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
authors.forename: B R
authors.initials: BR
authors.lastname: Murphy
authors.forename: G A
authors.initials: GA
authors.lastname: Prince
authors.forename: P L
authors.initials: PL
authors.lastname: Collins
authors.forename: K
authors.initials: K
authors.lastname: Van Wyke Coelingh
authors.forename: R A
authors.initials: RA
authors.lastname: Olmsted
authors.forename: M K
authors.initials: MK
authors.lastname: Spriggs
authors.forename: R H
authors.initials: RH
authors.lastname: Parrott
authors.forename: H W
authors.initials: HW
authors.lastname: Kim
authors.forename: C D
authors.initials: CD
authors.lastname: Brandt
authors.forename: R M
authors.initials: RM
authors.lastname: Chanock
mesh_terms: D000818:Animals; D000956:Antigens, Viral; D006801:Humans; D018184:Paramyxoviridae Infections / Q000517:prevention & control; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D018108:Respirovirus / Q000276:immunology*; D010253:Respirovirus Infections / Q000517:prevention & control; D014765:Viral Vaccines / Q000302:isolation & purification*
chemical_list: D000956:Antigens, Viral; D014765:Viral Vaccines